NCT06882317
Long Term Follow-up Study for Subjects Administered CLBR001
Enrolling by Invitation
Not specifiedAges 18+ObservationalCalibr, a division of Scripps ResearchInvestigator-initiated
~40 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Long Term Follow-Up
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with adverse events as assessed by CTCAE v5.0.
Measured over To 15 years post-CLBR001 administration.
+1 more outcome measured
Conditions
Where it's being run
3 sites across 3 statesIndiana1
North Carolina1
Virginia1
Study leadership
- Chief Medical Officer · STUDY_DIRECTOR · Calibr-Skaggs Institute for Innovative Medicines
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subjects who received at least one CLBR001 cell dose.
Exclusion
None
What this trial measures
- Number of subjects with adverse events as assessed by CTCAE v5.0.To 15 years post-CLBR001 administration.
To assess the long term safety of CLBR001 in subjects by evaluating the incidence, duration, and outcome of adverse events (including adverse events of special interest, CLBR001-related adverse events and serious adverse events), as assessed by CTCAE v5.0.
- Number of subjects with replication competent lentivirus (RCL).To 15 years post-CLBR001 administration.
To assess the long term safety of CLBR001 in subjects by evaluating the proportion of subjects with detectable RCL from CLBR001.